kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2022-11-4S-163-172kpccz-1272Research ArticleОНЛАЙН. АНАЛИТИЧЕСКИЙ ОБЗОР. КардиологияONLINE. REVIEW. CARDIOLOGYПатогенетические и клинические аспекты острого коронарного синдрома при гриппе и COVID-19: вопросы вакцинацииPathogenetic and clinical aspects of the development of acute coronary syndrome in influenza and COVID-19: vaccination issueshttps://orcid.org/0000-0003-0954-9270ЗыковМ. В.ZykovM. V.

Зыков Михаил Валерьевич - доктор медицинских наук, ведущий научный сотрудник лаборатории нейрососудистой патологии отдела клинической кардиологии НИИ КПССЗ; доцент кафедры медицинской реабилитации факультета повышения квалификации и профессиональной переподготовки специалистов КубГМУ МЗ РФ; врач-кардиолог отделения кардиологии № 1 ГБ № 4 г. Сочи МЗ Краснодарского края.

Сосновый бульвар, 6, Кемерово, 650002; ул. Митрофана Седина, 4, Краснодар, 350063; Туапсинская ул., 1, Сочи, 354057

Mikhail V. Zykov - PhD, Leading Researcher at the Laboratory of Neurovascular Pathology, Department of Clinical Cardiology, Research Institute for Complex Issues of Cardiovascular Diseases; Associate Professor, Department of Medical Rehabilitation, Faculty of Advanced Training and Professional Retraining of Specialists, Kuban State Medical University of the Ministry of Healthcare of the Russian Federation; Cardiologist at the Cardiology Department No. 1, City Hospital No. 4 of the Ministry of Healthcare of the Krasnodar Territory.

6, Sosnoviy Blvd., Kemerovo, 650002; 4, Mitrofan Sedin St., Krasnodar, 350063; 1, Tuapsinskaya St., Sochi, 354057

mvz83@mail.ruhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна - академик РАН, директор НИИ КПССЗ; заведующая кафедрой кардиологии и сердечно-сосудистой хирургии КемГМУ МЗ РФ.

Сосновый бульвар, 6, Кемерово, 650002; ул. Ворошилова, 22а, Кемерово, 650029

Olga L. Barbarash - Academician of the Russian Academy of Sciences, Director of the Research Institute for Complex Issues of Cardiovascular Diseases; Dean of the Faculty of Cardiology and Cardiovascular Surgery, Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation.

6, Sosnoviy Blvd., Kemerovo, Russian Federation, 650002; 22a, Voroshilova Str., Kemerovo, 650029

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Кубанский государственный медицинский университет Министерства здравоохранения Российской Федерации; Городская больница № 4 города Сочи Министерства здравоохранения Краснодарского краяРоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Kuban State Medical University of the Ministry of Health of the Russian Federation; State Hospital №4 of the Ministry of Healthcare of Krasnodar TerritoryRussian FederationНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; Кемеровский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University” of the Ministry of Health of the Russian FederationRussian Federation202202022023114Sприложение163172Copyright © Зыков М.В., Барбараш О.Л., 20232023Зыков М.В., Барбараш О.Л.Zykov M.V., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1272Основные положения

Основные положения. Пандемия новой коронавирусной инфекции определяет необходимость обязательной вакцинации пациентов высокого кардиоваскулярного риска, в частности после инфаркта миокарда, не только против COVID-19, но и гриппа, что является важным условием предотвращения дальнейшего роста смертности. При этом до сих пор сохраняется низкий процент охвата населения вакцинацией, что требует детального разбора не только клинической составляющей данной проблемы, но и патогенетической. Понимание врачом наиболее всесторонних аспектов проблемы позволит еще до получения данных специально спланированных исследований ускорить достижение успехов в лечении пациентов, перенесших инфаркт миокарда.

Резюме

Резюме. Настоящий обзор содержит современные данные о связи вирусных инфекций с повышением частоты развития сердечно-сосудистых катастроф, а также о роли вакцинации в улучшении прогноза острого коронарного синдрома. Поиск литературы проведен на сайтах кардиологических обществ, а также в базах данных PubMed, EMBASE, eLIBRARY.RU с использованием ключевых слов: «грипп», «новая коронавирусная инфекция (COVID-19)», «вакцинация», “SARS-CoV-2”, «острый коронарный синдром». Пандемия новой коронавирусной инфекции (COVID-19, COronaVIrus Disease 2019) определяет необходимость обязательной вакцинации пациентов с сердечно-сосудистыми заболеваниями не только против COVID-19, но и гриппа. Важность этого мероприятия, как явного условия предотвращения дальнейшего роста смертности от сердечно-сосудистых заболеваний, не должна вызывать сомнений. При этом до сих пор сохраняющийся низкий процент охвата населения вакцинацией способствует росту заболеваемости и смертности от сердечно-сосудистой патологии.

Highlights

Highlights. The new coronavirus infection necessitates mandatory vaccination of patients at high cardiovascular risk (in particular after myocardial infarction), including both COVID-19 vaccine and influenza vaccine, which represent an important condition for reducing mortality. At the same time, vaccination coverage among the population is still low, thus requiring a detailed analysis of clinical and pathogenetic components of this problem. The doctor's understanding of the most complex aspects of the problem will help achieve positive outcome in the treatment of patients who suffered from myocardial infarction, even before acquiring the data of specially planned studies.

Abstract

Abstract. This review contains current data on the relationship of viral infections with an increase in the incidence of cardiovascular diseases, as well as on the role of vaccination in improving the prognosis after myocardial infarction. The literature search was carried out by using the websites of cardiological societies, as well as the PubMed, EMBASE, eLibrary databases using the following keywords: flu, influenza, new coronavirus infection, SARS-CoV2, COVID-19, vaccination, acute coronary syndrome. The pandemic of COVID-19 (COronaVIrus Disease 2019) dictates the need for urgent vaccination against COVID-19 and influenza in patients with cardiovascular diseases. The importance of this measure, as a clear condition in preventing further increase in mortality from cardiovascular diseases, should not be doubted. At the same time, the still remaining low percentage of vaccinations is one of the causal factors of high rates of morbidity and mortality from cardiovascular pathology.

ВакцинацияГриппНовая коронавирусная инфекцияОстрый коронарный синдромVaccinationInfluenzaCOVID-19Acute coronary syndromeИсследование выполнено в рамках комплексной научно-технической программы полного инновационного цикла «Разработка и внедрение комплекса технологий в области разведки и добычи твердых полезных ископаемых, обеспечения промышленной безопасности, биоремедиации, создания новых продуктов глубокой переработки из угольного сырья при последовательном снижении экологической нагрузки на окружающую среду и рисков для жизни населения» (утв. Распоряжением Правительства РФ от 11 мая 2022 г. №1144-р).ReferencesTsang F.H., Chan W.C.C., Cho W.C.S., Yu A.C.S., Yim A.K.Y., Chan A.K.C., Ng L.P.W., Wong Y.K.E., Pei X.M., Li M.J.W., Wong S.C. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877-88. doi:10.1080/14787210.2021.1863146.Tsang F.H., Chan W.C.C., Cho W.C.S., Yu A.C.S., Yim A.K.Y., Chan A.K.C., Ng L.P.W., Wong Y.K.E., Pei X.M., Li M.J.W., Wong S.C. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877-88. doi:10.1080/14787210.2021.1863146.Российский статистический ежегодник. 2021. М.; 2021. 692 с.Russian Statistical Yearbook 2021. Мoscow; 2021. 692 p. (In Russian)Бойцов C. COVID-19 - серьезный фактор риска для сердца. Режим доступа: https://cardioweb.ru/news/item/3201-akademik-ran-sergej-bojtsov-covid-19-sereznyj-faktor-riska-dlya-serdtsa (дата обращения 12.05.2022)Boytsov S. COVID-19 is a serious risk factor for the heart. [Available at: https://cardioweb.ru/news/item/3201-akademik-ran-sergej-bojtsov-covid-19-sereznyj-faktor-riska-dlya-serdtsa (accessed 12.05.2022) (In Russian)Disease Burden of Flu. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). Available at: https://www.cdc.gov/flu/about/burden/index.html (accessed 14.12.2021).Disease Burden of Flu. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD). Available at: https://www.cdc.gov/flu/about/burden/index.html (accessed 14.12.2021).Nguyen J.L., Yang W., Ito K., Matte T.D., Shaman J., Kinney P.L. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1:274-81. doi:10.1001/jamacardio.2016.0433Nguyen J.L., Yang W., Ito K., Matte T.D., Shaman J., Kinney P.L. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1:274-81. doi:10.1001/jamacardio.2016.0433Arora A., Rout A., Satya K. Cardiovascular disease burden of influenza syndrome: national trends and outcomes from a United States population study from 2011 to 2014. J Am Coll Cardiol. 2019;73:1794. doi:10.1016/S0735-1097(19)32400-3.Arora A., Rout A., Satya K. Cardiovascular disease burden of influenza syndrome: national trends and outcomes from a United States population study from 2011 to 2014. J Am Coll Cardiol. 2019;73:1794. doi:10.1016/S0735-1097(19)32400-3.Caldeira D., Rodrigues B., David C., Costa J., Pinto F.J., Ferreira J.J. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Rev Vaccines. 2019;18(11):1211-17. doi:10.1080/14760584.2019.1690459.Caldeira D., Rodrigues B., David C., Costa J., Pinto F.J., Ferreira J.J. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Rev Vaccines. 2019;18(11):1211-17. doi:10.1080/14760584.2019.1690459.Chow E.J., Rolfes M.A., O’Halloran A., Anderson E.J., Bennett N.M., Billing L., Chai S., Dufort E., Herlihy R., Kim S., Lynfield R., McMullen C., Monroe M.L., Schaffner W., Spencer M., Talbot H.K., Thomas A., Yousey-Hindes K., Reed C., Garg S. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med. 2020;173:605–613. doi: 10.7326/M20-1509.Chow E.J., Rolfes M.A., O’Halloran A., Anderson E.J., Bennett N.M., Billing L., Chai S., Dufort E., Herlihy R., Kim S., Lynfield R., McMullen C., Monroe M.L., Schaffner W., Spencer M., Talbot H.K., Thomas A., Yousey-Hindes K., Reed C., Garg S. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med. 2020;173:605–613. doi: 10.7326/M20-1509.Iuliano A.D., Roguski K.M., Chang H.H., Muscatello D.J., Palekar R., Tempia S., Cohen C., Gran J.M., Schanzer D., Cowling B.J., Wu P., Kyncl J., Ang L.W., Park M., Redlberger-Fritz M., Yu H., Espenhain L., Krishnan A., Emukule G., van Asten L., Pereira da Silva S., Aungkulanon S., Buchholz U., Widdowson M.A., Bresee J.S.; Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285– 1300. doi: 10.1016/S0140-6736(17)33293-2.Iuliano A.D., Roguski K.M., Chang H.H., Muscatello D.J., Palekar R., Tempia S., Cohen C., Gran J.M., Schanzer D., Cowling B.J., Wu P., Kyncl J., Ang L.W., Park M., Redlberger-Fritz M., Yu H., Espenhain L., Krishnan A., Emukule G., van Asten L., Pereira da Silva S., Aungkulanon S., Buchholz U., Widdowson M.A., Bresee J.S.; Global Seasonal Influenza-associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285– 1300. doi: 10.1016/S0140-6736(17)33293-2.Udell J.A., Zawi R., Bhatt D.L., Keshtkar-Jahromi M., Gaughran F., Phrommintikul A., Ciszewski A., Vakili H., Hoffman E.B., Farkouh M.E., Cannon C.P. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711-20. doi:10.1001/jama.2013.279206.Udell J.A., Zawi R., Bhatt D.L., Keshtkar-Jahromi M., Gaughran F., Phrommintikul A., Ciszewski A., Vakili H., Hoffman E.B., Farkouh M.E., Cannon C.P. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310:1711-20. doi:10.1001/jama.2013.279206.Phrommintikul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A. I Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730-1735. doi:10.1093/eurheartj/ehr004.Phrommintikul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A. I Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730-1735. doi:10.1093/eurheartj/ehr004.Wu H.H., Chang Y.Y., Kuo S.C., Chen Y.T. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—A propensity score-matched follow-up study. PLoS ONE. 2019;14(7): e0219172. doi: 10.1371/journal.pone.0219172.Wu H.H., Chang Y.Y., Kuo S.C., Chen Y.T. Influenza vaccination and secondary prevention of cardiovascular disease among Taiwanese elders—A propensity score-matched follow-up study. PLoS ONE. 2019;14(7): e0219172. doi: 10.1371/journal.pone.0219172.Barnes M., Heywood A.E., Mahimbo A., Rahman B., Newall A.T., Macintyre C.R. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart. 2015;101:1738–47. doi: 10.1136/heartjnl-2015-307691.Barnes M., Heywood A.E., Mahimbo A., Rahman B., Newall A.T., Macintyre C.R. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart. 2015;101:1738–47. doi: 10.1136/heartjnl-2015-307691.Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas A.P., Douglas P.S., Foody J.M., Gerber T.C., Hinderliter A.L., King S.B. 3rd, Kligfield P.D., Krumholz H.M., Kwong R.Y., Lim M.J., Linderbaum J.A., Mack M.J., Munger M.A., Prager R.L., Sabik J.F., Shaw L.J., Sikkema J.D., Smith C.R. Jr., Smith S.C. Jr., Spertus J.A., Williams S.V.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons.2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. JACC. 2012;60(24):e44–e164. doi:10.1016/j.jacc.2012.07.013.Fihn S.D., Gardin J.M., Abrams J., Berra K., Blankenship J.C., Dallas A.P., Douglas P.S., Foody J.M., Gerber T.C., Hinderliter A.L., King S.B. 3rd, Kligfield P.D., Krumholz H.M., Kwong R.Y., Lim M.J., Linderbaum J.A., Mack M.J., Munger M.A., Prager R.L., Sabik J.F., Shaw L.J., Sikkema J.D., Smith C.R. Jr., Smith S.C. Jr., Spertus J.A., Williams S.V.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons.2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. JACC. 2012;60(24):e44–e164. doi:10.1016/j.jacc.2012.07.013.Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J., Gersh B.J., Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach S., Bax J.J.; ESC Scientific Document Group. . 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020;41:407-77. doi:10.1093/eurheartj/ehz425.Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J., Gersh B.J., Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach S., Bax J.J.; ESC Scientific Document Group. . 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020;41:407-77. doi:10.1093/eurheartj/ehz425.Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russian) doi:10.15829/29/1560-4071-2020-4076Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi:10.15829/29/1560-4071-2020-4103.2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russian) doi:10.15829/29/1560-4071-2020-41032021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42: 32273337. doi:10.1093/eurheartj/ehab4842021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42: 32273337. doi:10.1093/eurheartj/ehab484Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russian) doi:10.15829/1560-4071-2018-6-7-122.Fröbert О., Götberg M., Erlinge D., Akhtar Z., Christiansen E.H., MacIntyre C.R., Oldroyd K.G., Motovska Z., Erglis A., Moer R., Hlinomaz O., Jakobsen L., Engstrøm T., Jensen L.O., Fallesen C.O., Jensen S.E., Angerås O., Calais F., Kåregren A., Lauermann J., Mokhtari A., Nilsson J., Persson J., Stalby P., Islam A.K.M.M., Rahman A., Malik F., Choudhury S., Collier T., Pocock S.J., Pernow J. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18): 1476-84. doi:10.1161/CIRCULATIONAHA.121.057042.Fröbert О., Götberg M., Erlinge D., Akhtar Z., Christiansen E.H., MacIntyre C.R., Oldroyd K.G., Motovska Z., Erglis A., Moer R., Hlinomaz O., Jakobsen L., Engstrøm T., Jensen L.O., Fallesen C.O., Jensen S.E., Angerås O., Calais F., Kåregren A., Lauermann J., Mokhtari A., Nilsson J., Persson J., Stalby P., Islam A.K.M.M., Rahman A., Malik F., Choudhury S., Collier T., Pocock S.J., Pernow J. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18): 1476-84. doi:10.1161/CIRCULATIONAHA.121.057042.Grandhi G.R., Mszar R., Vahidy F., Valero-Elizondo J., Blankstein R., Blaha M.J., Virani S.S., Andrieni J.D., Omer S.B., Nasir K. Sociodemographic disparities in influenza vaccination among adults with atherosclerotic cardiovascular disease in the United States. JAMA Cardiol. 2021;6:87–89. doi:10.1001/jamacardio.2020.3978.Grandhi G.R., Mszar R., Vahidy F., Valero-Elizondo J., Blankstein R., Blaha M.J., Virani S.S., Andrieni J.D., Omer S.B., Nasir K. Sociodemographic disparities in influenza vaccination among adults with atherosclerotic cardiovascular disease in the United States. JAMA Cardiol. 2021;6:87–89. doi:10.1001/jamacardio.2020.3978.Bhugra P., Grandhi G.R., Mszar R., Satish P., Singh R., Blaha M., Blankstein R., Virani S.S., Cainzos-Achirica M., Nasir K. Determinants of Influenza Vaccine Uptake in Patients With Cardiovascular Disease and Strategies for Improvement. J Am Heart Assoc. 2021;10:e019671. doi:10.1161/JAHA.120.019671.Bhugra P., Grandhi G.R., Mszar R., Satish P., Singh R., Blaha M., Blankstein R., Virani S.S., Cainzos-Achirica M., Nasir K. Determinants of Influenza Vaccine Uptake in Patients With Cardiovascular Disease and Strategies for Improvement. J Am Heart Assoc. 2021;10:e019671. doi:10.1161/JAHA.120.019671.Katsoularis I., Fonseca-Rodríguez O., Farrington P., Lindmark K., Fors Connolly A.M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. The Lancet. 2021;398(10300):599-607. doi: 10.1016/S0140-6736(21)00896-5.Katsoularis I., Fonseca-Rodríguez O., Farrington P., Lindmark K., Fors Connolly A.M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. The Lancet. 2021;398(10300):599-607. doi: 10.1016/S0140-6736(21)00896-5.Modin D., Claggett B., Sindet-Pedersen C., Lassen M.C.H., Skaarup K.G., Jensen J.U.S., Fralick M., Schou M., Lamberts M., Gerds T., Fosbøl E.L., Phelps M., Kragholm K.H., Andersen M.P., Køber L., Torp-Pedersen C., Solomon S.D., Gislason G., Biering-Sørensen T. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142(21):2080– 82. doi: 10.1161/CIRCULATIONAHA.120.050809.Modin D., Claggett B., Sindet-Pedersen C., Lassen M.C.H., Skaarup K.G., Jensen J.U.S., Fralick M., Schou M., Lamberts M., Gerds T., Fosbøl E.L., Phelps M., Kragholm K.H., Andersen M.P., Køber L., Torp-Pedersen C., Solomon S.D., Gislason G., Biering-Sørensen T. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142(21):2080– 82. doi: 10.1161/CIRCULATIONAHA.120.050809.Bilaloglu S., Aphinyanaphongs Y., Jones S., Iturrate E., Hochman J., Berger J.S. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799–801. doi: 10.1001/jama.2020.13372.Bilaloglu S., Aphinyanaphongs Y., Jones S., Iturrate E., Hochman J., Berger J.S. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799–801. doi: 10.1001/jama.2020.13372.Lodigiani C., Iapichino G., Carenzo L., Cecconi M., Ferrazzi P., Sebastian T., Kucher N., Studt J.D., Sacco C., Bertuzzi A., Sandri M.T., Barco S.; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi: 10.1016/j.thromres.2020.04.024.Lodigiani C., Iapichino G., Carenzo L., Cecconi M., Ferrazzi P., Sebastian T., Kucher N., Studt J.D., Sacco C., Bertuzzi A., Sandri M.T., Barco S.; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi: 10.1016/j.thromres.2020.04.024.Yau J.W., Teoh H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015;15:130. doi: 10.1186/s12872-015-0124-z.Yau J.W., Teoh H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015;15:130. doi: 10.1186/s12872-015-0124-z.Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., Li W.W., Li V.W., Mentzer S.J., Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020;383:120–8. doi: 10.1056/NEJMoa2015432.Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., Li W.W., Li V.W., Mentzer S.J., Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020;383:120–8. doi: 10.1056/NEJMoa2015432.Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. Journal of virology. 2020;94(7):e00127-20. doi: 10.1128/JVI.00127-20.Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. Journal of virology. 2020;94(7):e00127-20. doi: 10.1128/JVI.00127-20.Santos R.A.S., Sampaio W.O., Alzamora A.C., Motta-Santos D., Alenina N., Bader M., Campagnole-Santos M.J. The ACE2/ angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505-53. doi:10.1152/physrev.00023.2016.Santos R.A.S., Sampaio W.O., Alzamora A.C., Motta-Santos D., Alenina N., Bader M., Campagnole-Santos M.J. The ACE2/ angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505-53. doi:10.1152/physrev.00023.2016.Шевченко О.П., Шевченко А.О. Ангиотензин II и инфаркт миокарда. Рациональная Фармакотерапия в Кардиологии. 2008;3:105-10.Shevchenko O.P., Shevchenko А.О. Angiotensin II and myocardial infarction. Rational Pharmacother. Card. 2008;3:105-10. (In Russian)Wang K., Gheblawi M., Oudit G.Y. Angiotensin converting enzyme 2: a double-edged sword. Circulation. 2020;142(5):426-428. doi:10.1161/CIRCULATIONAHA.120.047049.Wang K., Gheblawi M., Oudit G.Y. Angiotensin converting enzyme 2: a double-edged sword. Circulation. 2020;142(5):426-428. doi:10.1161/CIRCULATIONAHA.120.047049.Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118:1313–26. doi:10.1161/CIRCRESAHA.116.307708.Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/Angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118:1313–26. doi:10.1161/CIRCRESAHA.116.307708.Драпкина О.М., Васильева Л.Э. Спорные вопросы применения ингибиторов ангиотензинпревращающего фермента и антагонистов рецепторов ангиотензина у пациентов с COVID-19. Кардиоваскулярная терапия и профилактика. 2020;19(3):2580. doi:10.15829/1728-8800-2020-2580Drapkina O.M., Vasilyeva L.E. Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. Cardiovascular Therapy and Prevention. 2020;19(3):2580. (In Russian) doi:10.15829/1728-8800-2020-2580Libby P. Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1. Interleukin-6 and Beyond. Cells. 2021;10:951. doi:10.3390/cells10040951.Libby P. Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1. Interleukin-6 and Beyond. Cells. 2021;10:951. doi:10.3390/cells10040951.Dhama K., Patel S.K., Pathak M., Yatoo M.I., Tiwari R., Malik Y.S., Singh R., Sah R., Rabaan A.A., Bonilla-Aldana D.K., Rodriguez-Morales A.J. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med. Infect. Dis. 2020;37:101-755. doi: 10.1016/j.tmaid.2020.101755Dhama K., Patel S.K., Pathak M., Yatoo M.I., Tiwari R., Malik Y.S., Singh R., Sah R., Rabaan A.A., Bonilla-Aldana D.K., Rodriguez-Morales A.J. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med. Infect. Dis. 2020;37:101-755. doi: 10.1016/j.tmaid.2020.101755Болевич C.Б., Болевич С.С. Комплексный механизм развития СOVID-19. Сеченовский вестник. 2020;11(2):50-61. doi:10.47093/2218-7332.2020.11.2.50-61Bolevich S.B., Bolevich S.S. Complex mechanism of COVID-19 development. Sechenov medical journal. 2020;11(2): 50-61. (In Russian) doi:10.47093/2218-7332.2020.11.2.50-61Olbei M., Hautefort I., Modos D., Treveil A., Poletti M., Gul L., Shannon-Lowe C.D., Korcsmaros T. SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients. Front. Immunol. 2021;1;12:629193. doi: 10.3389/fimmu.2021.629193.Olbei M., Hautefort I., Modos D., Treveil A., Poletti M., Gul L., Shannon-Lowe C.D., Korcsmaros T. SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients. Front. Immunol. 2021;1;12:629193. doi: 10.3389/fimmu.2021.629193.Dua D., Yadav M., Jetley P., Dua R. Covid-19: Immunological lessons from bats, pangolins and old coronaviruses; and how we can apply them in a timely way for a better outcome. Preprints 2020, 2020040071. doi:10.20944/preprints202004.0071.v1.Dua D., Yadav M., Jetley P., Dua R. Covid-19: Immunological lessons from bats, pangolins and old coronaviruses; and how we can apply them in a timely way for a better outcome. Preprints 2020, 2020040071. doi:10.20944/preprints202004.0071.v1.Голота А.С., Камилова Т.А., Шнейдер О.В., Вологжанин Д.А., Щербак С.Г. Патогенез начальных стадий тяжелой формы COVID-19. Клиническая практика. 2021;12(2):83-102. doi:10.17816/clinpract71351.Golota A.S., Kamilova Т.А., Shneider О.V., Vologzhanin D.A., Sherbak S.G. Pathogenesis of the Initial Stages of Severe COVID-19. Journal of Clinical Practice. 2021;12(2):83-102. (In Russian) doi:10.17816/clinpract71351Zhang S., Liu Y., Wang X., Yang L., Li H., Wang Y., Liu M., Zhao X., Xie Y., Yang Y., Zhang S., Fan Z., Dong J., Yuan Z., Ding Z., Zhang Y., Hu L. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13(1):120. doi:10.1186/s13045-020-00954-7.Zhang S., Liu Y., Wang X., Yang L., Li H., Wang Y., Liu M., Zhao X., Xie Y., Yang Y., Zhang S., Fan Z., Dong J., Yuan Z., Ding Z., Zhang Y., Hu L. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13(1):120. doi:10.1186/s13045-020-00954-7.Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153-62. doi: 10.1016/j.blre.2014.10.003.Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29(3):153-62. doi: 10.1016/j.blre.2014.10.003.Nakamura S., Nakamura I., Ma L., Vaughan D.E., Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58:251-259. doi: 10.1046/j.1523-1755.2000.00160.xNakamura S., Nakamura I., Ma L., Vaughan D.E., Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58:251-259. doi: 10.1046/j.1523-1755.2000.00160.xTheofilis P., Sagris M., Oikonomou E., Antonopoulos A.S., Siasos G., Tsioufis C., Tousoulis D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9(7):781. doi:10.3390/biomedicines9070781.Theofilis P., Sagris M., Oikonomou E., Antonopoulos A.S., Siasos G., Tsioufis C., Tousoulis D. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9(7):781. doi:10.3390/biomedicines9070781.McCormack J.J., Silva M.L., Ferraro F., Patella F., Cutler D.F. Weibel-Palade bodies at a glance. J Cell Sci. 2017;130(21):3611-17. doi: 10.1242/jcs.208033.McCormack J.J., Silva M.L., Ferraro F., Patella F., Cutler D.F. Weibel-Palade bodies at a glance. J Cell Sci. 2017;130(21):3611-17. doi: 10.1242/jcs.208033.Anastasiou G., Gialeraki A., Merkouri E., Politou M., Travlou A. Thrombomodulin as a regulator of the anticoagulant pathway: Implication in the development of thrombosis. Blood Coagul. Fibrinolysis. 2012;23(1):1-10. doi: 10.1097/MBC.0b013e32834cb271.Anastasiou G., Gialeraki A., Merkouri E., Politou M., Travlou A. Thrombomodulin as a regulator of the anticoagulant pathway: Implication in the development of thrombosis. Blood Coagul. Fibrinolysis. 2012;23(1):1-10. doi: 10.1097/MBC.0b013e32834cb271.Sardu C., Gambardella J., Morelli M.B., Wang X., Marfella R., Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9(5):1417. doi:10.3390/jcm9051417.Sardu C., Gambardella J., Morelli M.B., Wang X., Marfella R., Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9(5):1417. doi:10.3390/jcm9051417.Shagdarsuren E., Wellner M., Braesen J.H., Park J.K., Fiebeler A., Henke N., Dechend R., Gratze P., Luft F.C., Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716-24. doi: https://doi.org/10.1161/01.RES.0000182677.89816.38Shagdarsuren E., Wellner M., Braesen J.H., Park J.K., Fiebeler A., Henke N., Dechend R., Gratze P., Luft F.C., Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716-24. doi: https://doi.org/10.1161/01.RES.0000182677.89816.38Rawish E., Sauter M., Sauter R. Complement, inflammation and thrombosis. J Pharmacol. 2021;178:2892-904. doi: 10.1111/bph.15476.Rawish E., Sauter M., Sauter R. Complement, inflammation and thrombosis. J Pharmacol. 2021;178:2892-904. doi: 10.1111/bph.15476.McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ. Res. 2020;127(4):571–87. doi: 10.1161/CIRCRESAHA.120.317447.McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ. Res. 2020;127(4):571–87. doi: 10.1161/CIRCRESAHA.120.317447.Guagliumi G., Sonzogni A., Pescetelli I., Pellegrini D., Finn A.V. Microthrombi and ST-Segment Elevation Myocardial Infarction in COVID-19. Circulation 2020;142:804–9. doi: 10.1161/CIRCULATIONAHA.120.049294.Guagliumi G., Sonzogni A., Pescetelli I., Pellegrini D., Finn A.V. Microthrombi and ST-Segment Elevation Myocardial Infarction in COVID-19. Circulation 2020;142:804–9. doi: 10.1161/CIRCULATIONAHA.120.049294.Cao W., Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30(5):367–369. doi:10.1038/s41422-020-0327-4.Cao W., Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30(5):367–369. doi:10.1038/s41422-020-0327-4.Guzik T., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M., Madhur M.S., Tomaszewski M., Maffia P., D'Acquisto F., Nicklin S.A., Marian A.J., Nosalski R., Murray E.C., Guzik B., Berry C., Touyz R.M., Kreutz R., Wang D.W., Bhella D., Sagliocco O., Crea F., Thomson E.C., McInnes I.B. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020;116 (10):1666–87. doi:10.1093/cvr/cvaa106.Guzik T., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M., Madhur M.S., Tomaszewski M., Maffia P., D'Acquisto F., Nicklin S.A., Marian A.J., Nosalski R., Murray E.C., Guzik B., Berry C., Touyz R.M., Kreutz R., Wang D.W., Bhella D., Sagliocco O., Crea F., Thomson E.C., McInnes I.B. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020;116 (10):1666–87. doi:10.1093/cvr/cvaa106.Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020;41(19):1798–1800. doi:10.1093/eurheartj/ehaa231.Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020;41(19):1798–1800. doi:10.1093/eurheartj/ehaa231.Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. от имени группы соавторов. Клинические особенности постковидного периода. Результаты международного регистра “Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARSCoV-2)”. Предварительные данные (6 месяцев наблюдения). Российский кардиологический журнал. 2021;26(10):4708. doi:10.15829/1560-4071-2021-4708.Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. on behalf of coauthors. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up. Russian Journal of Cardiology. 2021;26(10):4708. (In Russian) doi:10.15829/1560-4071-2021-4708Временные методические рекомендации профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 14 от 28.12.2021. Режим доступа: https://medvestnik.ru/content/documents/14-ot-27-12-2021.html (дата обращения14.07.2021)Interim guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13.1 from 11/17/2021. Available at: https://medvestnik.ru/content/documents/14-ot-27-12-2021.html (accessed 14/07/2021) (In Russian)Clar C., Oseni Z., Flowers N., Keshtkar-Jahromi M., Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;5:CD005050. doi:10.1002/14651858.CD005050.pub3.Clar C., Oseni Z., Flowers N., Keshtkar-Jahromi M., Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;5:CD005050. doi:10.1002/14651858.CD005050.pub3.Aye Y.N., Mai A.S., Zhang A., Lim O.Z.H., Lin N., Ng C.H., Chan M.Y., Yip J., Loh P.H., Chew N.W.S. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. 2021;hcab252. doi: 10.1093/qjmed/hcab252.Aye Y.N., Mai A.S., Zhang A., Lim O.Z.H., Lin N., Ng C.H., Chan M.Y., Yip J., Loh P.H., Chew N.W.S. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. 2021;hcab252. doi: 10.1093/qjmed/hcab252.Almas Т., Rehman S., Mansour E., Khedro T., Alansari A., Malik J., Alshareef N., Nagarajan V.R., Al-Awaid A.H., Alsufyani R., Alsufyani M., Rifai A., Alzahrani A., Nagarajan D.R., Abdullatif T., Gunasaegaram V., Alzadjali E., Subramanian A., Rahman A., Sattar Y., Galo J., Virk H.U.H., Alraies M.C. Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review. Biomedicine & Pharmacotherapy. 2022;149:112843. doi: 10.1016/j.biopha.2022.112843Almas Т., Rehman S., Mansour E., Khedro T., Alansari A., Malik J., Alshareef N., Nagarajan V.R., Al-Awaid A.H., Alsufyani R., Alsufyani M., Rifai A., Alzahrani A., Nagarajan D.R., Abdullatif T., Gunasaegaram V., Alzadjali E., Subramanian A., Rahman A., Sattar Y., Galo J., Virk H.U.H., Alraies M.C. Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review. Biomedicine & Pharmacotherapy. 2022;149:112843. doi: 10.1016/j.biopha.2022.112843

The authors declare that there are no conflicts of interest present.